Mountain Pacific Investment Advisers Inc. ID Sells 455 Shares of Catalent, Inc. (NYSE:CTLT)

Mountain Pacific Investment Advisers Inc. ID lessened its position in shares of Catalent, Inc. (NYSE:CTLT) by 0.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 192,043 shares of the company’s stock after selling 455 shares during the period. Mountain Pacific Investment Advisers Inc. ID’s holdings in Catalent were worth $8,628,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Gladius Capital Management LP bought a new stake in Catalent during the 3rd quarter worth approximately $28,000. Exchange Traded Concepts LLC bought a new stake in Catalent during the 3rd quarter worth approximately $31,000. GAMMA Investing LLC bought a new stake in Catalent during the 4th quarter worth approximately $33,000. Cary Street Partners Investment Advisory LLC increased its holdings in Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after acquiring an additional 709 shares during the period. Finally, Rakuten Securities Inc. bought a new position in shares of Catalent in the 4th quarter worth $46,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Barclays increased their price target on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. UBS Group reissued a “neutral” rating and issued a $63.50 price target (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Stephens reissued an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Finally, StockNews.com assumed coverage on shares of Catalent in a report on Saturday. They issued a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $52.46.

Catalent Trading Up 0.2 %

Shares of CTLT opened at $55.92 on Friday. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The firm has a fifty day simple moving average of $56.68 and a two-hundred day simple moving average of $48.70. Catalent, Inc. has a twelve month low of $31.45 and a twelve month high of $60.20.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The company’s quarterly revenue was down 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.62 EPS. As a group, equities analysts predict that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.